Minimal Residual Disease Analysis and its Impact after Hematopoietic Stem Cell Transplant for Acute Leukemias

The presence of minimal residual disease (MRD) at the time of Hematopoietic stem cell transplantation (HSCT) is well recognized as an adverse risk factor for poor outcomes in ALL and AML patients in morphologyc remission.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Caroline Bernardi, Aruana Legnani, Vaneuza Funke, Daniela Setubal, Michel Oliveira, Samir Nabhan, Caroline Bonamin, Marco Bittencout, Ricardo Pasquini, Mariester Malvezzi, Ana Paula Azambuja Source Type: research